Atai Beckley N.V.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersP7¹
• Incorporated inNetherlands²
• Business addressProf. J.H. Bavincklaan 7, Amstelveen, 1183²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Founded in 2018, atai emerged from the urgent need for better mental health solutions for patients who are under-served by current treatment options. We are advancing a pipeline of product candidates designed to address the complex nature of mental health disorders. We believe that these investigational compounds have the potential to become rapid-acting, durable, and commercially scalable therapies for mental health patients in need of new treatment options.⁴ From its latest annual report

Corporate structure

Atai Beckley N.V. sits at the top of its group. 15 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

What it owns

What Atai Beckley N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

Our principal executive office is located at Wallstraße 16, 10179, Berlin, Germany where we lease approximately 7,400 square feet of office space. The lease commenced in February 2023, and we will make payments over a five year term. We also lease office space in New York, New York. We believe that these facilities will be adequate for our near-term needs and that we will be able to renew these leases. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.

In October 2024 we acquired IntelGenx Corp. and assumed leases of approximately 43,000 square feet of office, lab, and manufacturing spaces in Montreal, Canada. The leases are set to expire in February 2026.

Item 2 of the 10-K filed Mar 17, 2025.⁴

Leadership

Who has led Atai Beckley N.V., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerAnne Nagengast Johnson Mar 15, 2024 to now¹²
• Chief financial officerStephen Bardin Aug 17, 2022 to Mar 16, 2023¹³
• Chief operating officerGerd Kochendoerfer Dec 13, 2024 to now¹⁴

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• EmpathBio, Inc. Delaware³
• GABA Therapeutics, Inc. Delaware³
• IntelGenx Corp. Canada³
• Perception Neuroscience Holdings, Inc. Delaware³
• PsyProtix, Inc. Delaware³
• Recognify Life Sciences, Inc. Delaware³
• atai Holdco, Inc. Delaware³
• atai Life Sciences AG Germany³
• atai Life Sciences UK Ltd England and Wales³
• atai Life Sciences US, Inc. Delaware³
• atai Therapeutics Holdings, Inc. Delaware³
• atai Therapeutics, Inc. (f.k.a. Viridia Life Sciences, Inc.) Delaware³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• ATAI Life Sciences N.V.Mar 4, 2021 to Nov 5, 2025²
• ATAI Life Sciences B.V.Feb 1, 2021 to Jun 21, 2021²

Timeline

1. Dec 5, 20258-K Other events³³
2. Nov 12, 20258-K Results of operations³⁴
3. Nov 5, 20258-K Completed an acquisition or sale; Unregistered sale of shares; Regulation FD disclosure³⁵
4. Nov 5, 20258-K Other events³⁶
5. Nov 4, 20258-K Shareholder vote³⁷
6. Oct 27, 20258-K Entered a material agreement; Other events³⁸
7. Oct 21, 20258-K Regulation FD disclosure; Other events³⁹
8. Oct 20, 20258-K Entered a material agreement; Results of operations; Regulation FD disclosure⁴⁰
9. Oct 16, 20258-K Regulation FD disclosure; Other events⁴¹
10. Oct 10, 20258-K Other events⁴²
11. Sep 29, 20258-K Other events⁴³
12. Sep 23, 20258-K Regulation FD disclosure; Other events⁴⁴

Calendar

When it reported results

1. Nov 12, 2025Reported quarterly or annual results³⁴
2. Oct 20, 2025Reported quarterly or annual results⁴⁰
3. Aug 14, 2025Reported quarterly or annual results⁴⁵
4. May 14, 2025Reported quarterly or annual results⁴⁶
5. Mar 17, 2025Reported quarterly or annual results⁴⁷
6. Nov 13, 2024Reported quarterly or annual results⁴⁸
7. Aug 13, 2024Reported quarterly or annual results⁴⁹
8. May 15, 2024Reported quarterly or annual results⁵⁰

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

250 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 59 major events, 105 insider forms, 9 large holders, 59 other. The latest 20:

1. Mar 20, 2026144 EDGAR
2. Feb 26, 2026144 EDGAR
3. Dec 31, 202515-12G EDGAR
4. Dec 31, 2025POSASR EDGAR
5. Dec 31, 2025S-8 POS EDGAR
6. Dec 5, 20258-K EDGAR
7. Dec 5, 2025424B7 EDGAR
8. Nov 26, 20254 EDGAR
9. Nov 12, 202510-Q EDGAR
10. Nov 12, 20258-K EDGAR
11. Nov 6, 20254 EDGAR
12. Nov 6, 20254 EDGAR
13. Nov 6, 20254 EDGAR
14. Nov 6, 20253 EDGAR
15. Nov 6, 20253 EDGAR
16. Nov 5, 20258-K EDGAR
17. Nov 5, 2025424B7 427B7 EDGAR
18. Nov 5, 20258-K EDGAR
19. Nov 4, 20258-K EDGAR
20. Oct 27, 2025425 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

30 open-market trades by officers, directors and large owners since October 2021: 21 buys and 9 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Apeiron Investment Group Ltd.SCHEDULE 13D/A, 7 filings Feb 10, 2022 to Oct 20, 2025⁵¹
• Galaxy Group Funding ECI U LLCSCHEDULE 13G/A, 2 filings Mar 1, 2022 to May 27, 2025⁵²

Stakes it holds

Atai Beckley N.V. has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

• Compass PathwaysSCHEDULE 13D/A Nov 29, 2021 to Oct 29, 2025⁵³
• IntelGenx Technologies Corp.SC 13D/A Sep 7, 2023 to May 3, 2024⁵⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Atai Beckley N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAtai Beckley N.V.¹
• CIK0001840904
• Employer ID (EIN)00-0000000⁴
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inNetherlands⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressProf. J.H. Bavincklaan 7, Amstelveen, 1183, Netherlands¹
• Phone49 89 2153 9035¹
• Shares outstanding363,190,522 as of Nov 10, 2025¹¹
• Public float$172.9M as of Jun 30, 2024⁴
• AuditorDELOITTE & TOUCHE LLP, New Jersey PCAOB ID 34; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceFeb 1, 2021¹
• Filings328 in all: 4 (113), 8-K (62), 3 (26), 144 (19), 10-Q (14), DEFA14A (13), CORRESP (8), SC 13D/A (6)¹
  All 40 form types

  424B5 (5), DEF 14A (5), PRE 14A (5), S-1/A (5), SCHEDULE 13D/A (5), 10-K (4), UPLOAD (4), 10-Q/A (2), 3/A (2), 4/A (2), 424B7 (2), EFFECT (2), SC 13D (2), SC 13G (2), SC 13G/A (2), SEC STAFF LETTER (2), 15-12G (1), 424B4 (1), 425 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), POSASR (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), S-8 (1), S-8 POS (1), SCHEDULE 13D (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 17, 2025
  Quarterly report (10-Q) Nov 12, 2025
  Proxy statement (DEF 14A) Apr 21, 2025
  Latest 8-K (8-K) Dec 5, 2025

Securities registered for trading

From the cover page of the 10-K filed Mar 17, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

Legal proceedings

We are, from time to time, party to various claims and legal proceedings arising in the ordinary course of our business. Given that such proceedings are subject to uncertainty, there can be no assurance that such legal proceedings, either individually or in the aggregate, will not have a material adverse effect on our business, results of operations, financial condition or cash flows. See Note 18, Commitments and Contingencies – Legal Proceedings, to our audited consolidated financial statements for additional information.

The opening of Item 3, Legal Proceedings.⁴